These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 25857559)

  • 21. Tuberculosis drug resistance: summary report for 2003.
    Can Commun Dis Rep; 2004 May; 30(10):93-5. PubMed ID: 15174496
    [No Abstract]   [Full Text] [Related]  

  • 22. Mycobacterial Biofilm: Mechanisms, Clinical Problems, and Treatments.
    Liu X; Hu J; Wang W; Yang H; Tao E; Ma Y; Sha S
    Int J Mol Sci; 2024 Jul; 25(14):. PubMed ID: 39063012
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The mycolic acids analysis with HPLC technique in drug susceptibility testing of Mycobacterium tuberculosis strains].
    Walkiewicz R; Grubek-Jaworska H; Chazan R
    Pneumonol Alergol Pol; 2006; 74(1):89-94. PubMed ID: 17175985
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recycling and refurbishing old antitubercular drugs: the encouraging case of inhibitors of mycolic acid biosynthesis.
    Belardinelli JM; Morbidoni HR
    Expert Rev Anti Infect Ther; 2013 Apr; 11(4):429-40. PubMed ID: 23566152
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Challenges and opportunities in tuberculosis drug discovery: an industry perspective.
    Shirude PS; Ramachandran S; Hosagrahara V
    Future Med Chem; 2013 Apr; 5(5):499-501. PubMed ID: 23573967
    [No Abstract]   [Full Text] [Related]  

  • 26. Mutations in the essential FAS II β-hydroxyacyl ACP dehydratase complex confer resistance to thiacetazone in Mycobacterium tuberculosis and Mycobacterium kansasii.
    Belardinelli JM; Morbidoni HR
    Mol Microbiol; 2012 Nov; 86(3):568-79. PubMed ID: 22994892
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Incidence of resistant mutants of Mycobacterium tuberculosis (MT) strains from different areas of Rumania. Bacteriological study--epidemiological aspects].
    Anastasatu C; Băicoianu S; Teodorescu A
    Arch Roum Pathol Exp Microbiol; 1970; 29(1):212-22. PubMed ID: 4998673
    [No Abstract]   [Full Text] [Related]  

  • 28. Targeting drug tolerance in mycobacteria: a perspective from mycobacterial biofilms.
    Islam MS; Richards JP; Ojha AK
    Expert Rev Anti Infect Ther; 2012 Sep; 10(9):1055-66. PubMed ID: 23106280
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Sensitivity of Mycobacterium tuberculosis in our environment].
    Unzaga MJ; Sota M; Melero P; Berdonces P; Ezpeleta C; Cisterna R
    Enferm Infecc Microbiol Clin; 1996; 14(6):399-400. PubMed ID: 8756225
    [No Abstract]   [Full Text] [Related]  

  • 30. Wild-type distributions of seven oral second-line drugs against Mycobacterium tuberculosis.
    Schön T; Juréen P; Chryssanthou E; Giske CG; Sturegård E; Kahlmeter G; Hoffner S; Angeby KA
    Int J Tuberc Lung Dis; 2011 Apr; 15(4):502-9. PubMed ID: 21396210
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Primary resistance of Mycobacterium tuberculosis].
    Blancarte L; Anzaldo de Jaime G; Balandrano S
    Salud Publica Mex; 1982; 24(3):321-7. PubMed ID: 6815813
    [No Abstract]   [Full Text] [Related]  

  • 32. Bioassay-guided isolation of a Mycobacterium tuberculosis bioflim inhibitor from Arisaema sinii Krause.
    Jiang CH; Gan ML; An TT; Yang ZC
    Microb Pathog; 2019 Jan; 126():351-356. PubMed ID: 30471433
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Phage amplified biologically assay and its application in rapid detection of Mycobacterium tuberculosis].
    Hu ZY
    Zhonghua Jie He He Hu Xi Za Zhi; 2004 Dec; 27(12):850-2. PubMed ID: 15730788
    [No Abstract]   [Full Text] [Related]  

  • 34. Molecule of the Month. TMC-207.
    Drug News Perspect; 2009 Sep; 22(7):421. PubMed ID: 19890499
    [No Abstract]   [Full Text] [Related]  

  • 35. Minimising moxifloxacin resistance with tuberculosis.
    Drlica K; Zhao X; Kreiswirth B
    Lancet Infect Dis; 2008 May; 8(5):273-5. PubMed ID: 18471768
    [No Abstract]   [Full Text] [Related]  

  • 36. [The achievements of the fundamental sciences and new approaches in the chemotherapy of tuberculosis].
    Egorov AM
    Probl Tuberk; 2000; (5):11-5. PubMed ID: 11077844
    [No Abstract]   [Full Text] [Related]  

  • 37. Pyrazinamide: a frontline drug used for tuberculosis. Molecular mechanism of action resolved after 50 years?
    Kalinda AS; Aldrich CC
    ChemMedChem; 2012 Apr; 7(4):558-60. PubMed ID: 22241617
    [No Abstract]   [Full Text] [Related]  

  • 38.
    Oluyori AP; Rode HB
    Future Med Chem; 2022 Feb; 14(4):203-205. PubMed ID: 34913388
    [No Abstract]   [Full Text] [Related]  

  • 39. Minding the gaps in tuberculosis research.
    Ekins S; Nuermberger EL; Freundlich JS
    Drug Discov Today; 2014 Sep; 19(9):1279-82. PubMed ID: 24993157
    [No Abstract]   [Full Text] [Related]  

  • 40. CDC advises on management of persons exposed to multiple-drug-resistant tuberculosis.
    Clin Pharm; 1992 Dec; 11(12):991, 994, 999. PubMed ID: 1337505
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.